Browsing by Author "Reljic, Vesna (55895308600)"

Introduction: This brief picture-oriented case report focuses on typical skin lesions in a patient who developed Ecthyma gangrenosum and pseudomonal sepsis after extensive immunosuppressive therapy for Pemphigus vulgaris. Case presentation: The patient was immunosuppressed with high doses of glucocorticoids and azathioprine; the follow-up after the treatment was not carried out well due to the pandemic conditions and because the patient herself got a Covid infection, which resulted in the development of pseudomonal sepsis and Ecthyma gangrenosum. The outcome was fatal despite extensive broad-spectrum antibiotic therapy, plasmapheresis, and intravenous immunoglobulins. Conclusions: Infections with Pseudomonas aeruginosa have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients, because of multi-drug resistance in the first place. Copyright © 2023 Tomanovic et al.

Introduction: This brief picture-oriented case report focuses on typical skin lesions in a patient who developed Ecthyma gangrenosum and pseudomonal sepsis after extensive immunosuppressive therapy for Pemphigus vulgaris. Case presentation: The patient was immunosuppressed with high doses of glucocorticoids and azathioprine; the follow-up after the treatment was not carried out well due to the pandemic conditions and because the patient herself got a Covid infection, which resulted in the development of pseudomonal sepsis and Ecthyma gangrenosum. The outcome was fatal despite extensive broad-spectrum antibiotic therapy, plasmapheresis, and intravenous immunoglobulins. Conclusions: Infections with Pseudomonas aeruginosa have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients, because of multi-drug resistance in the first place. Copyright © 2023 Tomanovic et al.

With the global introduction and widespread administration of COVID-19 vaccines, there have been emerging reports of associated vasculitis, including leukocytoclastic cutaneous vasculitis (LCV). In this paper, we present a case of a 68-year-old female patient who developed painful purpuric skin lesions on her feet 12 days after administration of the inactivated COVID-19 vaccine BBIBP Cor-V with histopathological confirmation of LCV and no signs of systemic involvement. The case is followed by a comprehensive literature review of documented LCV cases associated with COVID-19 vaccination with overall 39 articles and 48 cases of LCV found in total. In the majority of cases (56.3%) the first symptom occurred after the first dose of the COVID-19 vaccine, with symptoms manifesting within an average of seven days (6.8 ± 4.8) post-vaccination. The adenoviral vaccine Oxford-AstraZeneca (41.7%) and the mRNA vaccine Pfizer-BioNTech (27.1%) were most frequently associated with LCV occurrences. On average, LCV resolved within 2.5 (± 1.5) weeks. The preferred treatment modality were glucocorticoids, used in 70.8% of cases, resulting in a positive outcome in most cases, including our patient. While the safety of a subsequent dose appears favorable based on our review, individual risk–benefit assessment is crucial. This review emphasis the importance of considering COVID-19 vaccination as a potential trigger for the development of cutaneous vasculitis. Despite rare adverse events, the benefits of the COVID-19 vaccination outweigh the risks, highlighting the importance of immunization programs. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.

With the global introduction and widespread administration of COVID-19 vaccines, there have been emerging reports of associated vasculitis, including leukocytoclastic cutaneous vasculitis (LCV). In this paper, we present a case of a 68-year-old female patient who developed painful purpuric skin lesions on her feet 12 days after administration of the inactivated COVID-19 vaccine BBIBP Cor-V with histopathological confirmation of LCV and no signs of systemic involvement. The case is followed by a comprehensive literature review of documented LCV cases associated with COVID-19 vaccination with overall 39 articles and 48 cases of LCV found in total. In the majority of cases (56.3%) the first symptom occurred after the first dose of the COVID-19 vaccine, with symptoms manifesting within an average of seven days (6.8 ± 4.8) post-vaccination. The adenoviral vaccine Oxford-AstraZeneca (41.7%) and the mRNA vaccine Pfizer-BioNTech (27.1%) were most frequently associated with LCV occurrences. On average, LCV resolved within 2.5 (± 1.5) weeks. The preferred treatment modality were glucocorticoids, used in 70.8% of cases, resulting in a positive outcome in most cases, including our patient. While the safety of a subsequent dose appears favorable based on our review, individual risk–benefit assessment is crucial. This review emphasis the importance of considering COVID-19 vaccination as a potential trigger for the development of cutaneous vasculitis. Despite rare adverse events, the benefits of the COVID-19 vaccination outweigh the risks, highlighting the importance of immunization programs. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.

Background: Literature on the quality of life trends across time in children with atopic dermatitis are scarce. Aims: To assess factors associated with quality of life of children with atopic dermatitis after a one-year follow-up and to examine the factors contributing to greater improvement in the atopic dermatitis-related quality of life over one year. Methods: Our cohort consisted of 98 children who were treated for atopic dermatitis at the clinic of dermatovenereology. Data collection included atopic dermatitis scoring using the SCORing Atopic Dermatitis (SCORAD) index, Children’s Dermatology Life Quality Index (CDLQI) for children aged > four years and Infants’ Dermatitis Quality of Life Index (IDLQI) for children aged 0–4 years. Categorization of the impairment of quality of life score due to atopic dermatitis was as follows: mild (score from 0 to 6), moderate (score from 7 to 12) and severe (score from 13 to 30). The cohort was followed for one year after which a total of 80 children were reassessed. Results: Improvements of both CDLQI and IDLQI were observed in children whose impairment of quality of life due to atopic dermatitis after one year was ‘mild’. This was not observed in children whose atopic dermatitis caused either ‘moderate’ or ‘severe impairment’ of their quality of life. Adjusted analysis showed that lower initial SCORAD and greater improvement in SCORAD after the one-year follow-up were associated with a better quality of life at follow-up. Limitations: The size of our cohort was relatively small. Study participants were recruited from the largest urban and medical referral center in Serbia. Persons from suburban or rural regions may have had different perceptions of atopic dermatitis-related quality of life. Conclusion: Children with less severe atopic dermatitis were more likely to improve their atopic dermatitis-related quality of life. Lower SCORAD was associated with both better quality of life initially and greater improvement in quality of life after one year of follow-up. © 2022 Indian Journal of Dermatology, Venereology and Leprology - Published by Scientific Scholar

Introduction: Tuberculosis (TB) is a chronic, granulomatous, infectious disease caused by the Mycobacterium tuberculosis complex. Cutaneous TB accounts for less than 1–2% of all TB cases. Scrofuloderma is a subcutaneous form of cutaneous TB, which results from direct spreading of infection from deeper tissues. Case reports: We present two patients with scrofuloderma who exhibited typical clinical features but posed significant diagnostic challenges. In the first case, diagnosis was confirmed by polymerase chain reaction (PCR) of a tissue specimen which detected M. tuberculosis. All other microbiological tests, including direct microscopy, acid-fast bacilli smear, mycobacterial cultures, and TB-PCR of caseous discharge, were negative. In the second case, M. tuberculosis was identified via PCR of an ulcer swab, while other tests were negative. Histopathological findings were consistent with cutaneous TB. Both patients were treated with four first-line antitubercular drugs. The first patient developed progressive leukopenia and neutropenia and the treatment was adjusted to exclude ethambutol. Both the patients showed significant clinical improvement shortly after starting therapy. Conclusions: Cutaneous TB is often misdiagnosed due to its rarity and the challenges of microbiological testing, especially in paucibacillary forms. Histopathological features, though suggestive, are not pathognomonic, contributing to diagnostic delays. Increased awareness among dermatologists can lead to earlier diagnosis and better outcomes. Copyright © 2025 Skiljevic et al.

Introduction: Tuberculosis (TB) is a chronic, granulomatous, infectious disease caused by the Mycobacterium tuberculosis complex. Cutaneous TB accounts for less than 1–2% of all TB cases. Scrofuloderma is a subcutaneous form of cutaneous TB, which results from direct spreading of infection from deeper tissues. Case reports: We present two patients with scrofuloderma who exhibited typical clinical features but posed significant diagnostic challenges. In the first case, diagnosis was confirmed by polymerase chain reaction (PCR) of a tissue specimen which detected M. tuberculosis. All other microbiological tests, including direct microscopy, acid-fast bacilli smear, mycobacterial cultures, and TB-PCR of caseous discharge, were negative. In the second case, M. tuberculosis was identified via PCR of an ulcer swab, while other tests were negative. Histopathological findings were consistent with cutaneous TB. Both patients were treated with four first-line antitubercular drugs. The first patient developed progressive leukopenia and neutropenia and the treatment was adjusted to exclude ethambutol. Both the patients showed significant clinical improvement shortly after starting therapy. Conclusions: Cutaneous TB is often misdiagnosed due to its rarity and the challenges of microbiological testing, especially in paucibacillary forms. Histopathological features, though suggestive, are not pathognomonic, contributing to diagnostic delays. Increased awareness among dermatologists can lead to earlier diagnosis and better outcomes. Copyright © 2025 Skiljevic et al.

[No abstract available]

[No abstract available]